Erlotinib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00530 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Ewing sarcoma | KG + DL |
| 2 | fibromatosis, gingival | KG + DL |
| 3 | fibroma of lung | KG + DL |
| 4 | hamartoma of lung | KG + DL |
| 5 | lung benign neoplasm | KG + DL |
| 6 | lung hilum carcinoma | KG + DL |
| 7 | pulmonary sulcus neoplasm | KG + DL |
| 8 | lung germ cell tumor | KG + DL |
| 9 | inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia | KG + DL |
| 10 | junctional epidermolysis bullosa | KG + DL |
| 11 | Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome | KG + DL |
| 12 | ovarioleukodystrophy | KG + DL |
| 13 | junctional epidermolysis bullosa, non-Herlitz type | KG + DL |
| 14 | salivary gland type cancer of the breast | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.